In one trial, patients who took Wegovy lost an average of 14.9% of their body weight compared to 2.4% loss for patients on the placebo, according to Novo Nordisk
As a result, short-acting compared to long-acting GLP-1RAs are less effective in reducing fasting glucose and improving overall glucose control but are more effective in delaying gastric emptying and reducing glycemic excursion after meal ingestion (67)
Mechanism of Action Semaglutide mimics the naturally occurring hormone GLP-1, which your body releases after eating
However, as these are food supplements without officially established therapeutic doses, follow manufacturer instructions and consult a healthcare professional for personalised guidance
Common side effects include gastrointestinal issues, which lead to about 10% of patients discontinuing use, as well as risks like hypotension, pancreatitis, and the progression of diabetic retinopathy
How is Wegovy different from Ozempic or Zepbound